Age-related visual impairment is a prevalent condition that affects millions of people worldwide. With the aging...
The treatment of one of the most common urological diseases, a chronic aseptic prostatitis, is an exigeant problem. Used methods of pharmacotherapy are insufficiently effective and after treatment, as a rule, there comes a recrudescence. The new prostatotropic agent Prostamax is related to bioregulator peptides at experimental chronic aseptic inflammation of prostate gland. It is established that Prostamax reduces intensity of signs of a chronic inflammation, prevents development of sclerotic and atrophic processes and intensifies sexual activity of animals. Efficiency of the preparation Prostamax surpasses that among widespread prostatotropic agents derived from
Bremelanotide, also known as PT-141, is a peptide that binds to the body's MC3R and MC4R melanocortin receptors and is comparable to the alpha MSH and melanocortin. When it binds, it activates the hypothalamus and other brain areas, increasing sexual desire. Although it was once believed to be utilized to treat both male and female sexual problems, studies have shown that it is also effective in premenopausal women. Therefore, PT-141 is also employed in women who naturally have sexual abnormalities such as female sexual arousal disorder and hypoactive sexual desire. - The benefits of PT 141 Bremelanotide include: - Higher sex drive and increased sexual desire - Greater sexual frequency - Treatment for erectile dysfunction and/or impotence - Effective treatment for premenopausal women with Hypoactive Sexual Disorder - Sexual Dysfunction in women (Sexual Arousal Disorder) - Increased levels of natural energy.
Research indicates that TP508 can be used for: - stimulates the proliferation of stem cells - Stimulates revascularization - Reduces inflammation - Reduces cell apoptosis - Tissue regeneration and repair - Treatment for erectile dysfunction and/or impotence